IP Library Granted Patent US 8,377,987
Granted Patent B2
US 8,377,987 · App. 12/647,843 · Granted Feb 19, 2013

Compounds and uses thereof for treating inflammation and modulating immune responses

Inventors: Allan Sy Lau (Hong Kong, CN); Lai Hung Cindy Yang (Hong Kong, CN); Chi Chung Stanley Chik (Hong Kong, CN); Chun Bong James Li (Hong Kong, CN)
Assignees: PuraPharm Company Limited; Versitech Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,987
App. No.
12/647,843
Granted
Feb 19, 2013
Kind
B2
Abstract

The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.

Claims (20)

1. A method for treating arthritis, wherein said method comprises administering, to a subject in need of such treatment, an effective amount of an isolated compound or a salt thereof, wherein said compound has the following formula:

wherein

R 1 is alkyl;

R 2 is H or alkyl;

R 3 , R 4 , and R 5 are independently —H, acyl, halo, haloalkyl, amino, alkylamino, hydroxyl, alkyl, hydroxylalkyl, or —COOH;

R 6 is —O or —NH;

R 7 is —H, alkyl, alkoxy, hydroxylalkyl, hydroxyl, or halo;

R 8 , R 9 , and R 12 are independently —H, acyl, halo, amino, alkylamino, hydroxyl, alkyl, hydroxylalkyl, or —COOH;

R 10 is H or alkyl; and

R 11 is H or alkyl.

2. The method, according to claim 1 , wherein the subject is a human.

3. The method, according to claim 1 , wherein the R 2 is H, R 3 is H, and R 4 is H.

4. The method, according to claim 3 , wherein R 1 is a methyl group.

5. The method, according to claim 1 , wherein TNF-α activity is inhibited.

6. The method, according to claim 1 , used to rheumatoid arthritis.

7. The method, according to claim 1 , wherein the subject is a mammal.

8. The method, according to claim 7 , wherein the mammal is cattle.

9. The method, according to claim 1 , wherein ERK1/2 phosphorylation is inhibited.

10. The method, according to claim 1 , wherein said compound is:

11. The method, according to claim 1 , wherein NF-kB activation is suppressed.

Assignments (3)
CHANGE OF NAME Recorded Aug 25, 2014
From: PURAPHARM COMPANY LIMITED
To: BAGI RESEARCH LIMITED
Reel/Frame 033602/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2013
From: PURAPHARM INTERNATIONAL (H.K.) LIMITED; VERSITECH LIMITED
To: PURAPHARM COMPANY LIMITED; VERSITECH LIMITED
Reel/Frame 029556/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2012
From: LAU, ALLAN SY; YANG, LAI HUNG CINDY; CHIK, CHI CHUNG STANLEY; LI, CHUN BONG JAMES
To: PURAPHARM INTERNATIONAL (HK) LIMITED; VERSITECH LIMITED
Reel/Frame 029053/0199 →
Continuity (2)
Provisional Application 61143925 · Jan 12, 2009
Related Publication 20100184856A1 · Jul 22, 2010